Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern.

• Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) Comirnaty immunization, demonstrated robust antibody responses.

• Related: Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs.

• Neutralizing antibody concentrations were maintained between 15 and 29 days post-administration.

• These results are expected to support further clinical development of these candidates as booster vaccines.

• Price Action: ARCT shares are down 6.47% at $23.00 during the premarket session on Monday's last check.

See more from Benzinga

• Pfizer - OPKO Health's Growth Hormone Deficiency Candidate Receives FDA Response Letter

• Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.